Two Sigma Advisers LP Boosts Holdings in Guardant Health, Inc. (NASDAQ:GH)

Two Sigma Advisers LP increased its holdings in Guardant Health, Inc. (NASDAQ:GH) by 96.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,315,600 shares of the company’s stock after buying an additional 1,138,300 shares during the quarter. Two Sigma Advisers LP owned 1.87% of Guardant Health worth $70,742,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. R Squared Ltd purchased a new position in shares of Guardant Health during the 4th quarter valued at $26,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health during the 4th quarter valued at $43,000. Kimelman & Baird LLC purchased a new position in shares of Guardant Health during the 4th quarter valued at $58,000. NewEdge Advisors LLC lifted its stake in shares of Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after buying an additional 230 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Guardant Health during the 4th quarter valued at $61,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of the company’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the transaction, the chief executive officer now owns 2,202,672 shares in the company, valued at $107,952,954.72. This represents a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 107,132 shares of company stock valued at $5,249,355. 6.10% of the stock is currently owned by insiders.

Guardant Health Trading Down 1.1%

Shares of GH opened at $40.24 on Tuesday. Guardant Health, Inc. has a 12-month low of $20.14 and a 12-month high of $52.92. The firm has a fifty day moving average price of $43.75 and a 200-day moving average price of $39.88. The firm has a market capitalization of $4.99 billion, a P/E ratio of -11.30 and a beta of 1.49.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.08. The company had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.46) earnings per share. Analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on GH shares. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Canaccord Genuity Group boosted their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, May 1st. Morgan Stanley boosted their price target on shares of Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. Guggenheim reiterated a “buy” rating and set a $56.00 price objective on shares of Guardant Health in a research report on Monday, February 24th. Finally, Stephens reiterated an “overweight” rating and set a $55.00 price objective on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty-one investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $52.32.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.